Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Added

TDQS

A5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint, openWorldHint, idempotentHint, and destructiveHint=false. The description adds significant behavioral context: data sources (SEC EDGAR/XBRL, FAERS, FDA), handling of off-calendar fiscal years, sorted results by primary metric, and paired data with citation URIs. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with trigger phrases and a clear purpose. Each sentence adds value: parallel call efficiency, type-specific data, sorting behavior, and citations. Though moderately long, it is dense and free of redundancy.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description discloses return format (paired data + citation URIs), sorting behavior, and the specific data fields retrieved. It covers edge cases like off-calendar fiscal years. The only minor ambiguity is "primary metric," but overall it is complete for an agent to invoke correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% with descriptions for type and values, but the tool description adds substantial meaning: what each type pulls (company financials; drug adverse events), acceptable inputs for each (tickers/CIKs vs drug names), and the 2–5 range is reiterated with examples. This goes well beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool's purpose: side-by-side comparison of 2–5 companies or drugs in one parallel call. It uses specific trigger phrases like "Compare X and Y" and "X vs Y" and distinguishes itself from siblings by emphasizing it replaces sequential single-pack lookups.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description provides explicit usage guidance: "ALWAYS PREFER over sequential single-pack lookups when comparing entities" and gives concrete example intents (which is bigger/better, rank these companies). It differentiates between company and drug types and says it replaces 8–15 sequential lookups, implicitly telling when not to use single-entity tools.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.4/5.0
Disambiguation2/5

The tool set is a mix of country lookups and many unrelated Pipeworx tools (e.g., prediction markets, memory, subscriptions). While the country-specific tools are distinct, the overall set is a hodgepodge, making it difficult for an agent to determine which tools are relevant to a given task.

Naming Consistency2/5

Naming conventions are mixed: some use verb_noun (search_countries), some noun_verb (countries_by_currency), some single verbs (forget, recall), and some phrases (ai_visibility_check, ask_pipeworx). No consistent pattern is followed.

Tool Count1/5

35 tools is excessive for a server named 'countries'. Only about 6-7 tools are actually related to countries; the rest are unrelated (Pipeworx services, prediction markets, etc.), creating an extreme mismatch between the server name and its content.

Completeness2/5

For the country domain, the tool set includes search and lookups by code/currency/language/region but lacks basic CRUD, comparisons, maps, or sorting. Additionally, the presence of many unrelated tools dilutes completeness for the stated purpose.